Synergistic effect of CGS16949A and 5-fluorouracil on a human breast cancer cell line
| Autor: | M. Shibusawa, Kunihiko Fukuchi, Yoshinori Shimizu, Mitsuo Kusano, Yuko Tsunoda, Akira Tsunoda, Kentaroh Kamiya |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Antimetabolites
Antineoplastic Antineoplastic Agents Hormonal medicine.drug_class Breast Neoplasms Biology Thymidylate synthase Antimetabolite Breast cancer Aromatase medicine Tumor Cells Cultured Humans MTT assay Aromatase inhibitor Dose-Response Relationship Drug Fadrozole Cell Cycle Drug Synergism Cell cycle medicine.disease Biochemistry Fluorouracil Cell culture Cancer research biology.protein Surgery Female medicine.drug |
| Zdroj: | European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes. 33(3) |
| ISSN: | 0014-312X |
| Popis: | The effects of the aromatase inhibitor, CGS16949A, and the fluoropyrimidine, 5-fluorouracil (5-FU), on cell cycle distribution and growth were studied using FACS analysis and MTT assay in the human breast cancer cell line, SK-BR-3. CGS16949A induced an increase in the G0–G1 fraction on SK-BR-3 cells, and the growth inhibition rate of the combination of both (65.7 ± 3.0%) was significantly higher than 10 nM CGS16949A (37.9 ± 6.9%) or 100 µg/ml 5-FU (45.6 ± 4.5%); p < 0.01). Administering 5-FU after preincubation with CGS16949A significantly increased the combined cytotoxic efficacy, suggesting that clinical therapy using this combined therapy may be more efficient. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|